Clinical trial · Interventional
Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy
PET Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy
NCT05828238CI-TRIAL-00065919unknownEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single arm study to determining the value of apoptotic molecular probe SF-DEVD-2 in the early evaluation of tumor efficacy and comparing it head-to-head wihe 18F-FDG(18F-2-fluoro-2-deoxy-D-glucose)
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Stage II | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
| Breast Cancer Stage III | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [18F]-FDG | Drug | — | UNRESOLVED |
| [18F]SF-DEVD-2 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- [18F]SF-DEVD-2
- interventionNames
- Drug: [18F]SF-DEVD-2
- Drug: [18F]-FDG
Primary outcomes (1)
- measure
- Evaluation of tissue distribution of [18F]-DEVD-2
- timeFrame
- 7 days
- description
- Biodistribution of \[18F\] -DEVD-2 evaluated by the maximum standardized uptake value（SUVmax) in various organs during repeated \[18F\]-DEVD scans will be reported.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients voluntarily signed informed consent; 2. Age18-70, male or female; 3. Diagnosed with stage 2 or 3 breast cancer 4. Solid tumors、masses larger than 2cm with lymph node metastasis 5. Pathology is HER3+、triple negative patients 6. Patients to be treated with neoadjuvant chemotherapy Exclusion Criteria: 1. Age greater than or equal to 70 years old 2. Abnormal liver and kidney function (more than five times the normal value) 3. Diagnosis level of breast cancer stage 4 or second time tumor patients
References
Publications (0)
Data not yet available
No reference posted for this study.